Trial Profile

Phase II Clinical Trial of PLX038 in Patients With Platinum-Resistant Ovarian, Primary Peritoneal, and Fallopian Tube Cancer

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 30 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs DFP 13318 (Primary)
Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
Focus Therapeutic Use

Most Recent Events

23 Jul 2024 Planned End Date changed from 15 Feb 2025 to 31 Dec 2031.
23 Jul 2024 Planned primary completion date changed from 15 Feb 2025 to 15 May 2027.
04 Jun 2024 According to a Trial design presented at the 60th Annual Meeting of the American Society of Clinical Oncology, as of January 31, 2024, 12 of planned 37 patients have enrolled.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com